Peroxisomes in Different Skeletal Cell Types during Intramembranous and Endochondral Ossification and Their Regulation during Osteoblast Differentiation by Distinct Peroxisome Proliferator-Activated Receptors

PLoS One. 2015 Dec 2;10(12):e0143439. doi: 10.1371/journal.pone.0143439. eCollection 2015.

Abstract

Ossification defects leading to craniofacial dysmorphism or rhizomelia are typical phenotypes in patients and corresponding knockout mouse models with distinct peroxisomal disorders. Despite these obvious skeletal pathologies, to date no careful analysis exists on the distribution and function of peroxisomes in skeletal tissues and their alterations during ossification. Therefore, we analyzed the peroxisomal compartment in different cell types of mouse cartilage and bone as well as in primary cultures of calvarial osteoblasts. The peroxisome number and metabolism strongly increased in chondrocytes during endochondral ossification from the reserve to the hypertrophic zone, whereas in bone, metabolically active osteoblasts contained a higher numerical abundance of this organelle than osteocytes. The high abundance of peroxisomes in these skeletal cell types is reflected by high levels of Pex11β gene expression. During culture, calvarial pre-osteoblasts differentiated into secretory osteoblasts accompanied by peroxisome proliferation and increased levels of peroxisomal genes and proteins. Since many peroxisomal genes contain a PPAR-responsive element, we analyzed the gene expression of PPARɑ/ß/ɣ in calvarial osteoblasts and MC3T3-E1 cells, revealing higher levels for PPARß than for PPARɑ and PPARɣ. Treatment with different PPAR agonists and antagonists not only changed the peroxisomal compartment and associated gene expression, but also induced complex alterations of the gene expression patterns of the other PPAR family members. Studies in M3CT3-E1 cells showed that the PPARß agonist GW0742 activated the PPRE-mediated luciferase expression and up-regulated peroxisomal gene transcription (Pex11, Pex13, Pex14, Acox1 and Cat), whereas the PPARß antagonist GSK0660 led to repression of the PPRE and a decrease of the corresponding mRNA levels. In the same way, treatment of calvarial osteoblasts with GW0742 increased in peroxisome number and related gene expression and accelerated osteoblast differentiation. Taken together, our results suggest that PPARß regulates the numerical abundance and metabolic function of peroxisomes via Pex11ß in parallel to osteoblast differentiation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone and Bones / metabolism*
  • Bone and Bones / physiology
  • Cartilage / metabolism
  • Cartilage / physiology
  • Cell Differentiation / genetics
  • Cell Differentiation / physiology*
  • Cell Line
  • Chondrocytes / metabolism*
  • Chondrocytes / physiology
  • Gene Expression / genetics
  • Mice
  • Mice, Inbred C57BL
  • Osteocytes / metabolism*
  • Osteogenesis / genetics
  • Osteogenesis / physiology*
  • Peroxisome Proliferator-Activated Receptors / genetics
  • Peroxisome Proliferator-Activated Receptors / metabolism*
  • Peroxisomes / genetics
  • Peroxisomes / metabolism*
  • RNA, Messenger / genetics
  • Transcription, Genetic / genetics
  • Transcriptional Activation / genetics
  • Up-Regulation / genetics
  • Up-Regulation / physiology

Substances

  • Peroxisome Proliferator-Activated Receptors
  • RNA, Messenger

Grants and funding

The work was supported by Leistungsorientierte Mittel der Justus-Liebig University Giessen.